Regeneron Pharmaceuticals, Inc. $REGN Stake Raised by Westpac Banking Corp

Westpac Banking Corp increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 93.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,637 shares of the biopharmaceutical company’s stock after buying an additional 6,578 shares during the quarter. Regeneron Pharmaceuticals accounts for 0.6% of Westpac Banking Corp’s portfolio, making the stock its 26th biggest holding. Westpac Banking Corp’s holdings in Regeneron Pharmaceuticals were worth $10,341,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Berger Financial Group Inc bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $228,000. Ieq Capital LLC increased its position in shares of Regeneron Pharmaceuticals by 32.0% during the third quarter. Ieq Capital LLC now owns 63,500 shares of the biopharmaceutical company’s stock valued at $48,150,000 after purchasing an additional 15,395 shares during the period. Focus Advisor Solutions LLC increased its position in shares of Regeneron Pharmaceuticals by 287.9% during the third quarter. Focus Advisor Solutions LLC now owns 8,397 shares of the biopharmaceutical company’s stock valued at $6,367,000 after purchasing an additional 6,232 shares during the period. Checchi Capital Advisers LLC increased its position in shares of Regeneron Pharmaceuticals by 20.4% during the third quarter. Checchi Capital Advisers LLC now owns 550 shares of the biopharmaceutical company’s stock valued at $417,000 after purchasing an additional 93 shares during the period. Finally, Independent Advisor Alliance raised its stake in shares of Regeneron Pharmaceuticals by 10.1% in the third quarter. Independent Advisor Alliance now owns 829 shares of the biopharmaceutical company’s stock valued at $629,000 after purchasing an additional 76 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 4,466 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the completion of the transaction, the executive vice president directly owned 38,906 shares of the company’s stock, valued at approximately $37,563,353.94. This trade represents a 10.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christine A. Poon sold 7,830 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the completion of the sale, the director owned 5,219 shares in the company, valued at $5,057,680.71. This represents a 60.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 32,039 shares of company stock valued at $29,825,285. 6.97% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research reports. Cantor Fitzgerald raised their target price on Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an “overweight” rating in a research report on Monday, November 2nd. The Goldman Sachs Group lifted their price target on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Leerink Partners boosted their price target on shares of Regeneron Pharmaceuticals from $835.00 to $997.00 and gave the company a “market perform” rating in a report on Monday, November 2nd. Truist Financial boosted their price target on shares of Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the company a “buy” rating in a report on Monday, November 2nd. Finally, UBS Group upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $660.00 to $978.00 in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $904.41.

View Our Latest Stock Report on Regeneron Pharmaceuticals

Top Regeneron Pharmaceuticals Stories

Investors following REGN have been watching these stories:

  • Positive Sentiment: The FDA approved Livsayis (cemdisiran) for adults with anti-AChR-positive generalized myasthenia gravis. It is the first approved siRNA therapy for the disease and the only treatment described as requiring just four subcutaneous doses per year. Approval was based on Phase 3 results showing sustained disease control. Livsayis is Regeneron’s first marketed RNAi drug and its first neurology medicine. Reuters article
  • Positive Sentiment: The European Commission approved more flexible Libtayo dosing across six cancer indications. Less frequent infusions and shorter administration times could improve convenience and support use of Regeneron’s oncology drug. Libtayo dosing article
  • Negative Sentiment: Livsayis will enter a market with established treatments from AstraZeneca and Argenx, so commercial uptake and competition will influence how much the approval adds to Regeneron’s results. Market competition article

Regeneron Pharmaceuticals Stock Down 2.3%

NASDAQ REGN opened at $923.34 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $591.52 and a 1-year high of $991.73. The company has a market capitalization of $95.52 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 1.25 and a beta of 0.10. The stock’s 50 day moving average is $826.97 and its two-hundred day moving average is $751.27. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. Regeneron Pharmaceuticals’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $11.83 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.30%.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.